Shattuck Labs, Inc. (NASDAQ:STTK) Stock Has Consensus Target Price of $13.70

Key Points

• Analysts are broadly positive on Shattuck Labs: 12 of 13 rate the stock Buy or Strong Buy, with a consensus 1-year price target of $13.70.
• Institutional investors and hedge funds own 58.74% of the shares; State Street increased its stake by 67.4% in the third quarter.
• Shares recently traded at $4.65, well below the consensus target, and the company’s latest quarterly loss of $0.14 per share was wider than analysts’ expected $0.11 loss.

Shattuck Labs, Inc. (NASDAQ:STTK - Get Free Report) has been assigned a consensus rating of "Buy" from the thirteen analysts that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, nine have issued a buy recommendation and three have assigned a strong buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $13.70.

A number of brokerages have weighed in on STTK. Leerink Partners initiated coverage on shares of Shattuck Labs in a research report on Monday, July 20th. They set an "outperform" rating and a $16.00 price target for the company. Wall Street Zen lowered shares of Shattuck Labs from a "hold" rating to a "sell" rating in a report on Saturday, November 7th. HC Wainwright decreased their price objective on shares of Shattuck Labs from $18.00 to $14.00 and set a "buy" rating on the stock in a report on Tuesday, August 11th. TD Cowen raised shares of Shattuck Labs to a "strong-buy" rating in a research report on Monday, August 24th. Finally, Wedbush lifted their target price on shares of Shattuck Labs from $11.00 to $14.00 and gave the company an "outperform" rating in a report on Friday, October 2nd.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Empowered Funds LLC acquired a new stake in shares of Shattuck Labs in the third quarter valued at $284,000. State Street Corp raised its holdings in shares of Shattuck Labs by 67.4% in the 3rd quarter. State Street Corp now owns 3,435,783 shares of the company's stock valued at $23,432,000 after buying an additional 1,382,995 shares during the period. Voya Investment Management LLC raised its holdings in shares of Shattuck Labs by 30.7% in the 3rd quarter. Voya Investment Management LLC now owns 15,389 shares of the company's stock valued at $105,000 after buying an additional 3,611 shares during the period. Fisher Asset Management LLC acquired a new position in Shattuck Labs during the 3rd quarter worth about $575,000. Finally, Profund Advisors LLC acquired a new position in Shattuck Labs during the 3rd quarter worth about $195,000. 58.74% of the stock is currently owned by institutional investors and hedge funds.

Shattuck Labs Price Performance

Shares of NASDAQ:STTK traded down $0.16 during midday trading on Friday, reaching $4.65. 775,897 shares of the company's stock were exchanged, compared to its average volume of 964,645. The stock has a market cap of $473.56 million, a price-to-earnings ratio of -9.12 and a beta of 1.21. Shattuck Labs has a fifty-two week low of $1.72 and a fifty-two week high of $8.33. The firm's 50 day simple moving average is $5.80 and its two-hundred day simple moving average is $6.04.

Shattuck Labs (NASDAQ:STTK - Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.03). Equities research analysts predict that Shattuck Labs will post -0.51 earnings per share for the current fiscal year.

Shattuck Labs Company Profile

Shattuck Labs, Inc. is a clinical-stage biotechnology company developing medicines that modulate the immune system to treat cancer. The company's research has centered on biologic therapies designed to combine immune checkpoint inhibition with activation of immune cells. Its lead candidate, SL-172154, is an engineered fusion protein designed to block the CD47 “don't eat me” signal and activate CD40, with the aim of promoting an antitumor immune response. Shattuck has evaluated the candidate in clinical studies for cancers including ovarian cancer and higher-risk myelodysplastic syndromes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.